Comparison of naveibine and cisplatin versus gemcitabine and cisplatin in refractory metastatic breast cancer / 肿瘤研究与临床

0.05).The degreeⅢ～Ⅳthrombocytopenia was more common in group A than in group B,but the degreeⅢ～Ⅳhypolekocytosis and phlebitis was more serious in group B.Conclusion NC and GC for treating refractory metastatic breast cancer have a high response rate and tolerable side effects.